Corcept Therapeutics (CORT) stock price, revenue, and financials

Corcept Therapeutics market cap is $2 b, and annual revenue was $306.49 m in FY 2019

$2 B

CORT Mkt cap, 23-Sept-2020

$88.6 M

Corcept Therapeutics Revenue Q2, 2020
Corcept Therapeutics Gross profit (Q2, 2020)87.3 M
Corcept Therapeutics Gross profit margin (Q2, 2020), %98.6%
Corcept Therapeutics Net income (Q2, 2020)28.3 M
Corcept Therapeutics EBIT (Q2, 2020)35.3 M
Corcept Therapeutics Cash, 30-Jun-202058.5 M
Corcept Therapeutics EV1.9 B

Corcept Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

3.3m10.4m26.6m50.3m81.3m159.2m251.2m306.5m

Revenue growth, %

156%89%62%

Cost of goods sold

91.0k143.0k882.0k1.4m2.1m3.6m5.2m5.5m

Gross profit

3.2m10.2m25.7m48.9m79.3m155.6m246.0m301.0m

Gross profit Margin, %

97%99%97%97%97%98%98%98%

R&D expense

21.0m14.1m15.4m23.8m40.4m75.2m89.0m

General and administrative expense

11.3m25.4m31.2m34.9m36.9m45.2m62.4m81.3m100.4m

Operating expense total

32.3m39.5m31.2m34.9m52.4m69.1m102.8m156.5m189.4m

EBIT

(32.3m)(36.3m)(41.5m)(27.6m)(3.4m)10.2m52.9m89.5m111.6m

EBIT margin, %

(1097%)(401%)(104%)(7%)13%33%36%36%

Interest expense

1.7m4.5m3.8m2.0m

Interest income

3.0k

Pre tax profit

52.8m92.2m116.7m

Income tax expense

(76.3m)16.7m22.5m

Net Income

(32.4m)(38.0m)(46.0m)(31.4m)(6.4m)8.1m129.1m75.4m94.2m

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

875.0k1.1m1.7m1.9m2.6m4.4m5.9m7.3m10.1m12.0m13.3m16.1m19.7m21.7m27.6m35.6m42.8m57.7m62.3m64.4m64.8m72.3m81.5m93.2m88.6m

Cost of goods sold

48.0k24.0k20.0k23.0k40.0k174.0k215.0k235.0k302.0k439.0k256.0k403.0k426.0k668.0k646.0k775.0k976.0k1.2m1.2m1.3m1.2m1.4m1.5m1.9m1.2m

Gross profit

827.0k1.0m1.7m1.9m2.6m4.2m5.6m7.0m9.8m11.5m13.0m15.7m19.3m21.1m27.0m34.8m41.8m56.5m61.2m63.1m63.6m70.9m80.1m91.4m87.3m

Gross profit Margin, %

95%98%99%99%98%96%96%97%97%96%98%97%98%97%98%98%98%98%98%98%98%98%98%98%99%

R&D expense

6.2m3.2m3.5m2.7m3.0m4.3m4.5m5.2m7.3m4.3m3.0m4.4m3.3m3.6m4.6m5.7m7.1m7.2m7.9m11.7m17.1m20.5m18.9m20.2m21.7m22.8m26.1m26.5m

General and administrative expense

2.7m3.2m7.5m5.8m5.7m8.4m8.2m7.2m9.8m8.0m9.1m9.5m9.3m9.3m10.4m12.1m10.9m15.0m14.1m16.5m18.4m20.0m21.3m24.4m24.6m24.2m27.5m25.6m

Operating expense total

8.9m6.4m11.0m8.4m8.7m12.6m12.7m12.3m17.1m12.2m12.2m13.8m12.7m12.9m15.1m17.8m18.0m22.2m22.0m28.2m35.5m40.5m40.2m44.6m46.2m47.1m53.7m52.1m

Depreciation and amortization

48.0k

EBIT

(8.9m)(6.4m)(11.0m)(7.6m)(7.7m)(10.9m)(10.8m)(9.7m)(12.9m)(6.6m)(5.1m)(4.0m)(1.2m)102.0k592.0k1.5m3.1m4.7m12.8m13.6m21.0m20.6m23.0m19.0m24.6m33.0m37.7m35.3m

EBIT margin, %

(868%)(727%)(637%)(570%)(370%)(292%)(112%)(70%)(40%)(10%)1%4%8%14%17%36%32%36%33%36%29%34%40%40%40%

Interest expense

1.1m1.1m1.2m1.1m971.0k903.0k800.0k770.0k703.0k611.0k531.0k487.0k225.0k1.2m1.3m

Interest income

1.0k3.0k

Pre tax profit

4.5m12.7m13.7m21.3m21.2m23.7m20.1m25.8m34.4m39.2m36.3m

Income tax expense

127.0k50.0k(48.0k)3.8m3.0m6.0m1.8m5.6m8.0m9.1m7.9m

Net Income

(8.9m)(6.4m)(11.0m)(7.6m)(8.3m)(12.1m)(11.9m)(10.9m)(13.9m)(7.6m)(6.0m)(4.8m)(1.9m)(601.0k)(19.0k)977.0k2.6m4.4m12.6m13.8m17.5m18.2m17.7m18.3m20.2m26.3m30.1m28.3m

Corcept Therapeutics Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

52.2m45.9m42.6m34.9m101.6m81.5m72.2m63.2m43.6m34.0m26.8m38.0m37.0m36.5m40.7m41.8m47.9m38.0m33.6m31.1m33.1m31.2m33.9m49.7m58.1m44.9m84.5m58.5m

Accounts Receivable

355.0k354.0k1.1m855.0k1.0m1.9m2.2m2.7m4.3m5.0m5.9m6.8m9.3m8.2m9.2m9.5m11.9m17.3m28.7m19.4m19.2m19.8m22.4m26.7m22.7m

Prepaid Expenses

455.0k427.0k102.0k608.0k800.0k572.0k801.0k1.0m1.5m2.2m1.8m622.0k1.2m1.2m1.1m1.6m1.4m1.8m2.5m3.1m3.3m3.6m4.3m5.7m6.2m7.8m5.7m5.3m

Inventories

56.0k2.4m1.8m1.0m694.0k1.0m1.1m1.1m1.1m1.3m1.5m1.6m1.9m2.1m2.3m2.9m3.1m3.8m4.9m4.9m5.4m5.0m5.1m5.5m5.1m4.9m

Current Assets

52.7m46.3m42.8m38.3m104.6m84.2m74.6m66.2m48.1m39.4m32.4m44.2m44.7m45.2m50.5m54.8m59.8m66.7m81.3m93.9m150.8m197.2m224.2m216.9m232.7m267.3m344.8m438.3m

PP&E

3.0k3.0k30.0k59.0k105.0k154.0k139.0k184.0k285.0k296.0k273.0k230.0k173.0k143.0k93.0k76.0k145.0k302.0k499.0k553.0k577.0k552.0k540.0k925.0k1.2m1.2m880.0k619.0k

Total Assets

52.7m46.4m42.9m38.6m105.5m88.1m79.7m71.1m52.8m44.4m37.2m48.2m48.4m48.4m52.9m56.8m62.9m75.3m86.5m110.7m243.0m274.4m299.8m320.2m328.7m367.0m445.5m497.8m

Accounts Payable

2.3m1.1m2.1m4.2m1.6m2.3m3.0m2.3m3.7m2.6m2.0m1.0m2.4m1.7m2.1m2.1m4.3m4.3m2.1m6.2m7.9m6.4m13.9m9.3m7.0m5.9m5.0m6.3m

Short-term debt

2.3m3.9m3.7m4.5m6.9m7.4m8.7m10.7m12.0m13.5m16.3m18.6m18.7m10.1m4.6m1.6m2.0m

Current Liabilities

3.9m2.7m3.6m5.8m5.5m8.2m9.1m10.1m15.2m13.3m12.5m15.5m17.4m18.8m24.0m27.4m31.7m25.8m20.4m24.4m27.7m30.9m40.2m34.2m30.4m32.4m34.1m42.2m

Long-term debt

28.3m28.9m30.2m30.1m28.2m27.6m26.0m22.1m19.4m16.1m8.7m3.7m1.5m1.5m

Total Debt

30.6m32.8m33.9m34.6m35.1m35.0m34.7m32.8m31.4m29.6m25.0m22.3m18.7m10.1m4.6m3.1m3.5m

Total Liabilities

34.5m30.6m32.6m36.0m44.1m

Common Stock

84.0k84.0k89.0k89.0k100.0k100.0k100.0k100.0k101.0k101.0k101.0k108.0k108.0k109.0k110.0k110.0k111.0k113.0k113.0k114.0k115.0k116.0k116.0k118.0k118.0k119.0k120.0k121.0k

Preferred Stock

Additional Paid-in Capital

241.0m242.2m258.8m259.9m307.0m309.6m310.9m312.2m315.8m317.4m318.7m339.3m342.2m344.7m350.5m355.0m358.0m367.4m371.3m377.7m391.0m401.0m408.2m427.3m436.6m446.6m465.5m481.7m

Retained Earnings

(192.2m)(198.6m)(219.6m)(258.7m)(270.6m)(281.5m)(306.5m)(314.1m)(320.1m)(328.8m)(330.8m)(331.4m)(330.4m)(329.4m)(326.9m)(317.9m)(305.2m)(291.5m)(175.7m)(157.5m)(139.7m)(99.5m)(79.3m)(52.9m)6.5m34.8m

Total Equity

48.9m43.7m39.3m32.8m71.7m51.0m40.4m30.8m9.4m3.5m(1.3m)10.6m11.5m13.5m20.2m25.7m31.2m49.6m66.1m86.3m215.2m243.5m259.5m285.8m298.1m334.4m409.5m453.7m

Financial Leverage

1.1 x1.1 x1.1 x1.2 x1.5 x1.7 x2 x2.3 x5.6 x12.9 x-28.2 x4.6 x4.2 x3.6 x2.6 x2.2 x2 x1.5 x1.3 x1.3 x1.1 x1.1 x1.2 x1.1 x1.1 x1.1 x1.1 x1.1 x

Corcept Therapeutics Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(16.0m)(22.4m)(11.0m)(18.6m)(26.9m)(12.1m)(24.0m)(34.9m)(13.9m)(21.5m)(27.5m)(4.8m)(6.8m)(7.4m)(19.0k)958.0k3.5m4.4m17.0m30.8m17.5m35.7m53.4m18.3m38.5m64.8m30.1m58.4m

Depreciation and Amortization

1.0k1.0k3.0k8.0k23.0k14.0k33.0k53.0k28.0k65.0k104.0k40.0k97.0k127.0k27.0k51.0k72.0k13.0k22.0k58.0k48.0k105.0k163.0k96.0k263.0k474.0k238.0k362.0k

Accounts Receivable

(355.0k)(354.0k)(586.0k)(298.0k)(462.0k)(494.0k)(797.0k)(1.3m)(967.0k)(1.6m)(2.6m)(531.0k)(3.1m)(2.0m)646.0k356.0k(2.0m)(2.0m)(13.4m)(4.1m)(1.6m)(2.2m)(4.8m)(6.8m)(2.8m)

Inventories

(56.0k)(2.4m)(2.5m)(13.0k)(881.0k)(892.0k)89.0k(94.0k)38.0k257.0k426.0k703.0k290.0k388.0k(825.0k)(1.5m)(1.1m)(344.0k)590.0k(2.1m)(4.3m)910.0k(1.5m)(654.0k)1.3m1.4m

Accounts Payable

1.5m249.0k(1.5m)624.0k(2.0m)(1.5m)(771.0k)(1.5m)1.3m214.0k(421.0k)(850.0k)474.0k(146.0k)757.0k756.0k3.0m2.0m(216.0k)3.9m(759.0k)(2.2m)5.3m953.0k(1.3m)(2.4m)(2.6m)(1.3m)

Cash From Operating Activities

(14.5m)(21.1m)(10.2m)(18.0m)(27.3m)(11.6m)(20.8m)(29.4m)(11.1m)(20.0m)(26.0m)(1.8m)(1.9m)(1.0m)3.3m4.9m13.8m9.6m25.1m36.1m34.4m49.6m94.1m23.7m49.2m87.7m33.3m86.5m

Purchases of PP&E

(7.0k)(41.0k)(93.0k)(18.0k)(22.0k)(87.0k)(110.0k)(158.0k)(174.0k)(34.0k)(34.0k)(34.0k)(22.0k)(29.0k)(119.0k)(110.0k)(308.0k)(390.0k)(77.0k)(140.0k)(185.0k)(257.0k)(667.0k)(953.0k)(42.0k)(89.0k)

Cash From Investing Activities

(7.0k)(41.0k)(93.0k)(18.0k)(22.0k)(87.0k)(110.0k)(158.0k)(174.0k)(34.0k)(34.0k)(34.0k)(22.0k)(29.0k)(119.0k)(19.4m)(34.4m)(46.0m)(34.3m)(55.5m)(89.0m)(367.0k)(1.5m)(55.8m)19.7m(66.2m)

Long-term Borrowings

(378.0k)(995.0k)(2.0m)(3.3m)(1.9m)(4.0m)(6.4m)(3.0m)(6.3m)(10.3m)(4.8m)(10.5m)(15.1m)

Cash From Financing Activities

42.2m42.4m13.2m13.4m89.4m(378.0k)(89.0k)(701.0k)(1.9m)15.5m14.8m13.3m(3.0m)(3.5m)(6.3m)(3.7m)(8.7m)(10.5m)1.9m6.0m(2.3m)(15.3m)(31.2m)(28.5m)205.0k7.0m

Net Change in Cash

27.7m21.3m3.0m(4.7m)62.0m(11.6m)(20.8m)(29.9m)(11.3m)(20.9m)(28.1m)13.7m12.8m12.2m309.0k1.4m7.4m(13.6m)(17.9m)(20.5m)2.1m103.0k2.8m8.0m16.5m3.3m53.2m27.3m

Corcept Therapeutics Ratios

USDQ2, 2011

Financial Leverage

1.1 x

Corcept Therapeutics Employee Rating

3.79 votes
Culture & Values
3.8
Work/Life Balance
3.4
Senior Management
3.5
Salary & Benefits
4.3
Career Opportunities
3.6
Source